Although more than half of Americans misuse prescription drugs, the percentage that did so has held steady for four consecutive years, according to a new analysis. Meanwhile, though, there has also been a surge in the use of illicit drugs and medicines obtained without a prescription among patients being treated for substance use disorders.

The overall rate at which drugs were misused was 52 percent last year, according to an analysis of approximately 3.9 million laboratory test results that were stripped of identifying patient information. The so-called misuse rate has barely budged since 2014, but marks a notable decline from the 63 percent rate found in 2011, according to Quest Diagnostics (DGX), the laboratory testing company, which conducted the analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Nowhere does this article or the C.D.C define Misuse. Random pharmaceuticals were given to people who were already addicted to heroin or other drugs. Pharma companies marketed their products as beneficial even though there was no evidence to support their claims. When these people already dependent on an illicit drug were then seen “overdosing” or abusing the recommended prescribed pharma products which did not relieve the symptoms or treat their drug dependence, these people were added to the numbers of overdoses and misuse. No effort to track any of this was done, even though there were a lot of deaths. Fact based research was not done, it would have interfered with pharma profits. The Opioid debacle was turned into a marketing campaign.

    People with chronic pain are regularly forced to try alternatives, meaning the Pharma Industry marketed drugs that showed little or no effect on chronic pain, as a replacement for opiates. They marketed anti depressants, drugs like Gabapentin, and even anti psychotics, that had no effect on pain. They count the patients lack of relief, side effects , or even the cost, as misuse. Deliberately conflating Misuse with Addiction for a reason. Even discontinuing a pharmaceutical is counted as misuse.

    • Hi Mavis,
      Thanks for your note.
      There is a link in the post to the Quest report, which includes this:

      “For clinicians, drug monitoring can provide insights into possible forms of misuse including: substance use disorders, dangerous drug combinations, incomplete treatment, and/or “diversion” – instances where the
      prescribed drug is not found in the patient’s specimen, suggesting the patient is possibly filling the prescription, but may be diverting the drug to others or opted not to take it.”

      Perhaps that helps somewhat.
      Regards
      ed at pharmalot

  • Sentinel cannot live up to its promise and interchangeable EHR’s are a forlorn hope (to date) but Quest can simply study the real population, drawing conclusions from what data sources (where are those firewalls?), and we accept it. “How bizarre!”

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy